Bioceres Crop Solutions Corp. (NASDAQ: BIOX): Corporate Profile & Financials
Source: Bioceres Crop Solutions Corp. Form 20-F Fiscal Year 2026
📋 Quick Facts / Company Snapshot
| Corporate Snapshot Key Metric | Official Disclosed Value |
|---|---|
| Official Name | Bioceres Crop Solutions Corp. |
| Ticker Symbol | BIOX |
| Primary Exchange | Nasdaq Capital Market (Transferred from Nasdaq Global Select Market on September 18, 2026) |
| Principal Executive Offices | Ocampo 210 bis, Predio CCT, Rosario, Province of Santa Fe, Argentina |
| Industry / Sector | Agricultural Biotechnology & Crop Productivity Solutions |
| Founded | 2001 (Bioceres S.A. founded in 2001; Bioceres Crop Solutions Corp. incorporated November 14, 2017) |
| Total Employees | 562 full-time employees (Continuing operations as of June 30, 2026) |
| Key Operational Locations | Rosario (Argentina), Pergamino (Argentina), Londrina (Brazil) |
| Patents & Intellectual Property | Over 180 patents and patent applications; 1,250+ trademarks worldwide |
| Principal Subsidiaries | BCS Holding Inc., Bioceres Crops do Brasil Ltda., Bioceres Crops S.A., Bioceres Semillas S.A.U., Comer. Agrop. Rizobacter de Bolivia S.A., Insumos Agroquímicos S.A., Pro Farm Group, Inc., Rasa Holding LLC, Rizobacter Argentina S.A., Rizobacter Colombia SAS, Rizobacter del Paraguay S.A., Rizobacter do Brasil Ltda., Rizobacter France SAS, Rizobacter South Africa, Rizobacter Uruguay, Rizobacter USA, LLC, Verdeca LLC |
| Parent Company | Bioceres Group Limited (Former parent company; deconsolidated following Bioceres S.A. bankruptcy in March 2026) |
| Chief Executive Officer | Federico Trucco, Ph.D. |
| Chief Financial Officer | Ezequiel Simmermacher |
| External Website | www.biocerescrops.com |
🏢 The Corporate Identity: Who They Are & Where They Came From
The Big Picture
Bioceres Crop Solutions Corp. is a fully integrated agricultural biotechnology enterprise focused on developing and commercializing productivity solutions designed to regenerate agricultural ecosystems while enhancing crop resilience to climate change. Operating globally, the group develops climate-smart ag-tech products that incentivize farmers to adopt sustainable production methods without sacrificing economic yields.
The company maintains a broad intellectual property portfolio featuring high-impact, licensed, and patented technologies spanning seeds, microbial ag-inputs, biological crop protection, and next-generation crop nutrition. Its solutions target major agricultural challenges, including drought stress, soil degradation, and pest management, across key commercial row crops such as soybeans, wheat, and corn.
- Broad Product Portfolio: Owns or licenses over 1,250 registered brands, 600 registered products, and over 180 patents and patent applications globally.
- Global Reach: Agricultural inputs marketed across more than 45 countries in South America, North America, Europe, Africa, and Asia.
- Extensive Commercial Access: Direct and indirect access to growers via a commercial sales force of 148 professionals and relationships with over 1,600 dealers and distributors.
The Founders & Their Legacy
Bioceres was originally established in Argentina in 2001 by a group of forward-thinking agricultural producers and agronomists seeking to address the growing demand for higher crop yields through sustainable, science-based practices. The founders included prominent farm operators, processors, distributors, and early leaders of the sustainable agriculture movement in Latin America, notably founding members of the Argentine Association of Direct Seeding Producers (AAPRESID) and regional consortia members (AACREA).
This producer-led heritage created an open-architecture development model that directly connects scientific discovery with real-world farming applications. This historical origin provided Bioceres with immediate access to a built-in network of early-adopter farmers who served as a validation testing ground for newly commercialized seed traits and microbial solutions.
The Journey: History & Evolution
Over two decades, Bioceres evolved from an Argentine agricultural research network into a publicly traded global biotech platform through targeted acquisitions, research joint ventures, and international commercial partnerships.
In October 2016, the company made a transformative move by acquiring a controlling 50.01% equity stake in Rizobacter Argentina S.A., a global pioneer in liquid inoculants, high-tech adjuvants, and specialty fertilizers with a history spanning over 45 years. Bioceres subsequently expanded its ownership in Rizobacter to 80% in March 2019.
- Public Listing via Business Combination (2019): Completed a business combination with Union Acquisition Corp. on March 14, 2019, listing its ordinary shares on the NYSE American under the ticker symbol BIOX, and later transferring its listing to The Nasdaq Stock Market in April 2021.
- Full Ownership of Verdeca (2020): Acquired the remaining 50% interest in Verdeca LLC from Arcadia Biosciences in November 2020, gaining full control over the HB4 soybean trait library and exclusive Latin American rights to Arcadia’s quality wheat traits.
- Pro Farm Merger & Strategic Pivot (2022–2026): Merged with Pro Farm Group, Inc. (formerly Marrone Bio Innovations) in July 2022 to strengthen its biological crop protection portfolio. Following a 2025 default acceleration on its Secured Notes, the collateral pledged by Pro Farm was subject to a judicial foreclosure auction in January 2026, leading to the reclassification of Pro Farm as a discontinued operation.
- Syngenta Global Distribution Deal (2022–2026): Executed a 10-year exclusive global distribution agreement with Syngenta Crop Protection in September 2022 for biological seed care solutions, receiving a $50 million upfront license payment, which was subsequently amended in January 2026 to refine commercial targets and distribution scope.
The Corporate Umbrella
Bioceres Crop Solutions Corp. is an exempted company incorporated under the laws of the Cayman Islands on November 14, 2017. The group functions as a holding company operating through direct and indirect operating subsidiaries located across Argentina, Brazil, the United States, Uruguay, Paraguay, Bolivia, Colombia, France, and South Africa.
Historical corporate structures linked Bioceres Crop Solutions to Bioceres S.A. and Bioceres Group Limited. In March 2026, Bioceres S.A. entered judicial bankruptcy proceedings in Argentina, resulting in the loss of control and deconsolidation of Bioceres S.A. and Bioceres LLC by Bioceres Group Limited, shifting the governance dynamic of historical parent entities.
⚙️ The Business Engine: What They Do & Where They Operate
The Core Divisions
The company conducts its continuing business operations through three primary reportable business segments: Crop Protection, Seed & Integrated Products, and Crop Nutrition. Each division targets distinct aspects of the crop production lifecycle, combining biological tools, chemical formulations, and seed technologies.
| Business Segment | Key Product Lines | Fiscal Year 2026 Revenue (in $ millions) | Fiscal Year 2026 Gross Margin (%) |
|---|---|---|---|
| Crop Protection | Adjuvants, biopesticides, biofungicides, bionematicides, pest control molecules | 123.7 | 34% |
| Seed & Integrated Products | HB4 drought-tolerant seed traits, elite germplasm, custom seed treatment packs | 37.7 | 46% |
| Crop Nutrition | Micro-beaded starter fertilizers, nitrogen-fixing liquid inoculants, biofertilizers, biostimulants | 77.0 | 31% |
The Global Product Catalog
Bioceres offers an extensive portfolio of sustainable agricultural solutions designed to maximize crop yield potential while reducing environmental impact:
- HB4 Drought Tolerance Technology: A patented plant biotechnology trait derived from sunflower genetics that confers tolerance to abiotic stresses, particularly drought and salinity. HB4 increases soybean and wheat yields by an average of 10% to 20% under water-stressed conditions without incurring a yield penalty under optimal growing environments.
- Microgranular Starter Fertilizers (Microstar): Formulated micro-beaded fertilizers applied directly alongside seeds at planting. Microstar provides immediate availability of essential nutrients like nitrogen, phosphorus, sulfur, and zinc at reduced application rates (20 to 30 kg/ha replacing 80 kg/ha of conventional fertilizers).
- Biological Seed Inoculants: Liquid inoculants containing nitrogen-fixing bacteria (such as Bradyrhizobium) for leguminous crops like soybeans. Includes Ultra High Concentrate (UHC) and Extended Shelf Life formulations for professional seed treatment.
- High-Tech Adjuvants: Specialized tank-mix additives that optimize spraying performance, enhance active ingredient absorption, reduce chemical application doses, and limit environmental runoff.
- Biocontrol & Biofungicides: Microbial pest control solutions including Rizoderma, a biofungicide based on Trichoderma strains for seed and soilborne disease control.
The Names You Know
The group markets its technology catalog through several proprietary brands and trademarked product families:
- HB4®: The signature drought and stress-tolerance technology platform for wheat and soybeans.
- Rizobacter®: The global brand identity for biological seed treatment, inoculants, and crop protection products.
- Microstar PZ® & CMB Bio®: Premium micro-beaded fertilizer lines combining chemical nutrients with beneficial bacterial inoculants.
- Rizoderma®: Proprietary biological fungicide formulation for seed treatment.
- Bioceres Semillas®: The internal seed distribution brand used in South America.
Mapping the Global Reach
Bioceres generates the majority of its revenues from agricultural markets in Latin America, while expanding its footprint across North America, Europe, and southern Africa. South America—specifically Argentina—represents the primary commercial hub.
| Geographic Region (in $ actual) | Fiscal Year 2026 Revenue | Fiscal Year 2025 Revenue | Fiscal Year 2024 Revenue | Latest YoY (%) |
|---|---|---|---|---|
| Argentina | 200,549,303 | 232,034,876 | 351,778,631 | -13.57% |
| Brazil | 9,917,166 | 14,861,671 | 13,671,110 | -33.27% |
| LATAM (Excl. Argentina & Brazil) | 14,840,808 | 18,581,425 | 21,590,901 | -20.13% |
| Rest of the World (ROW) | 12,528,048 | 22,183,085 | 33,397,897 | -43.52% |
| Total Consolidated Revenues | 237,835,325 | 287,661,057 | 420,438,539 | -17.32% |
The Brick & Mortar Footprint
Bioceres operates manufacturing, research, and logistics assets concentrated in South America, designed with a light fixed-asset structure that offers spare capacity for global scaling:
- Pergamino Manufacturing Complex (Argentina): The primary operational hub featuring an adjuvant plant (2.1 million gallons annual capacity), two biological production plants (combined 1.87 million gallons capacity), a fungicide/insecticide formulation facility (1.0 million gallons capacity), a micro-beaded fertilizer plant operated via Synertech (50,000 tons capacity), and over 375,000 square feet of warehousing space.
- Londrina Adjuvant Plant (Brazil): A high-tech adjuvant manufacturing facility completed in Paraná, Brazil, boasting an annual production capacity of approximately 2.6 million gallons to service the Brazilian market.
- Research & Development Facilities: Primary research laboratories and field testing stations located in Pergamino and Rosario, Argentina, equipped for microbiology, bioprocess scaling, chemistry, and seed breeding.
📊 The Financial Health: The Global Numbers Simplified
Earnings, Expenses, & Take-Home Profits
The following table sets forth the full formal Consolidated Statements of Comprehensive Income of Bioceres Crop Solutions Corp. for the fiscal years ended June 30, 2026, 2025, and 2024, presenting continuing operations separately from discontinued operations.
| Consolidated Statement of Comprehensive Income (in $ actual) | Fiscal Year 2026 | Fiscal Year 2025 | Fiscal Year 2024 | Latest YoY (%) |
|---|---|---|---|---|
| Revenues from contracts with customers | 237,835,325 | 287,661,057 | 420,438,539 | -17.32% |
| Initial recognition and changes in the fair value of biological assets at the point of harvest | 441,141 | 1,764,863 | (45,746) | -75.00% |
| Cost of sales | (155,095,436) | (184,384,992) | (263,035,619) | -15.89% |
| Changes in the net realizable value of agricultural products after harvest | (346,277) | (1,540,776) | (2,385,069) | -77.53% |
| Research and development expenses | (11,033,441) | (9,455,598) | (8,372,532) | +16.69% |
| Selling, general and administrative expenses | (71,227,886) | (93,701,345) | (96,974,913) | -23.98% |
| Share of profit or loss of joint ventures and associates | 216,110 | (1,126,312) | 4,049,508 | N/M |
| Other income or expenses, net | (24,198,391) | 7,380,799 | (1,539,458) | N/M |
| Operating (loss) / profit | (23,408,855) | 6,597,696 | 52,134,710 | N/M |
| Financial cost | (39,923,224) | (25,078,507) | (24,809,708) | +59.19% |
| Other financial results | (12,148,207) | (28,036,711) | (5,069,215) | -56.67% |
| (Loss) / Profit before income tax | (75,480,286) | (46,517,522) | 22,255,787 | +62.26% |
| Income tax | (6,957,743) | (2,618,488) | (6,603,649) | +165.72% |
| (Loss) / Profit of the year from continuing operations | (82,438,029) | (49,136,010) | 15,652,138 | +67.78% |
| Discontinued operations | (199,719) | (9,709,243) | (8,363,155) | -97.94% |
| Loss related to foreclosure | (181,305,248) | 0 | 0 | N/M |
| Loss of the year from discontinued operations | (181,504,967) | (9,709,243) | (8,363,155) | +1769.40% |
| (Loss) / Profit of the year | (263,942,996) | (58,845,253) | 7,288,983 | +348.54% |
| Total Comprehensive (Loss) / Profit | (261,419,839) | (59,559,504) | 6,501,629 | +338.92% |
Assets, Debts, & Corporate Wealth
The following table sets forth the full formal Consolidated Statements of Financial Position of Bioceres Crop Solutions Corp. as of June 30, 2026, and June 30, 2025.
| Consolidated Statement of Financial Position (in $ actual) | As of June 30, 2026 | As of June 30, 2025 | Latest YoY (%) |
|---|---|---|---|
| Cash and cash equivalents | 11,242,958 | 32,695,079 | -65.61% |
| Other financial assets (Current) | 1,001,241 | 2,040,038 | -50.92% |
| Trade receivables (Current) | 98,211,154 | 165,859,933 | -40.79% |
| Other receivables (Current) | 12,060,759 | 15,861,981 | -23.96% |
| Recoverable income tax (Current) | 1,445,908 | 1,864,817 | -22.46% |
| Inventories | 46,408,777 | 87,611,269 | -47.03% |
| Biological assets | 594,543 | 2,378,380 | -75.00% |
| Assets subject to foreclosure | 44,430,378 | 0 | N/M |
| Total Current Assets | 215,395,718 | 308,311,497 | -30.14% |
| Other financial assets (Non-current) | 0 | 58 | -100.00% |
| Trade receivables (Non-current) | 731,919 | 2,506,834 | -70.80% |
| Other receivables (Non-current) | 16,228,480 | 23,660,530 | -31.41% |
| Recoverable income tax (Non-current) | 0 | 17,995 | -100.00% |
| Deferred tax assets | 274,314 | 4,916,980 | -94.42% |
| Investments in joint ventures and associates | 40,780,055 | 39,371,264 | +3.58% |
| Investment properties | 0 | 570,324 | -100.00% |
| Property, plant and equipment | 60,655,861 | 74,575,386 | -18.67% |
| Intangible assets | 74,655,056 | 181,173,079 | -58.79% |
| Goodwill | 28,550,361 | 112,163,432 | -74.55% |
| Right of use asset | 10,956,448 | 16,377,701 | -33.10% |
| Total Assets | 448,228,212 | 763,645,080 | -41.30% |
| Trade and other payables (Current) | 57,674,444 | 96,432,604 | -40.19% |
| Borrowings (Current) | 47,260,267 | 119,728,126 | -60.53% |
| Employee benefits and social security (Current) | 4,846,155 | 6,174,012 | -21.51% |
| Deferred revenue and advances from customers (Current) | 2,140,338 | 4,282,668 | -50.02% |
| Income tax payable | 4,866,139 | 452,800 | +974.68% |
| Consideration for acquisition (Current) | 42,564 | 1,761,274 | -97.58% |
| Secured notes (Current) | 121,956,575 | 102,270,445 | +19.25% |
| Lease liabilities (Current) | 2,108,964 | 6,884,042 | -69.36% |
| Liabilities subject to foreclosure | 29,430,378 | 0 | N/M |
| Total Current Liabilities | 270,325,824 | 337,985,971 | -20.02% |
| Trade and other payables (Non-current) | 41,956,936 | 48,481,726 | -13.46% |
| Borrowings (Non-current) | 59,982,642 | 38,198,026 | +57.03% |
| Deferred revenue and advances from customers (Non-current) | 1,436,912 | 1,436,912 | 0.00% |
| Joint ventures and associates (Non-current liability) | 1,092,995 | 1,007,678 | +8.47% |
| Deferred tax liabilities | 23,907,907 | 30,122,920 | -20.63% |
| Provisions | 6,325,454 | 1,267,572 | +399.02% |
| Consideration for acquisition (Non-current) | 359,846 | 397,774 | -9.54% |
| Lease liabilities (Non-current) | 8,781,609 | 9,527,939 | -7.83% |
| Total Liabilities | 414,170,125 | 468,426,518 | -11.58% |
| Total Equity | 34,058,087 | 295,218,562 | -88.46% |
Cash Flow: Tracking the Money Movement
The following table sets forth the full formal Consolidated Statements of Cash Flows of Bioceres Crop Solutions Corp. for the fiscal years ended June 30, 2026, 2025, and 2024.
| Consolidated Statement of Cash Flows (in $ actual) | Fiscal Year 2026 | Fiscal Year 2025 | Fiscal Year 2024 | Latest YoY (%) |
|---|---|---|---|---|
| Loss of the year | (263,942,996) | (58,845,253) | 7,288,983 | +348.54% |
| Loss of the year from discontinued operations | 181,504,967 | 9,709,243 | 8,363,155 | +1769.40% |
| Income tax | 6,957,743 | 2,618,488 | 6,603,649 | +165.72% |
| Financial results | 52,071,431 | 53,115,218 | 29,878,923 | -1.97% |
| Depreciation of property, plant and equipment | 5,908,863 | 4,724,278 | 4,481,546 | +25.07% |
| Amortization of intangible assets | 6,543,341 | 6,113,503 | 4,978,718 | +7.03% |
| Depreciation of leased assets | 3,334,114 | 4,313,516 | 2,337,840 | -22.71% |
| Other contingencies | 3,499,866 | 0 | 0 | N/M |
| Impairment of intangible assets and goodwill | 15,584,021 | 0 | 0 | N/M |
| Impairment of other receivables from joint ventures and associates | 7,667,621 | 0 | 0 | N/M |
| Other restructuring and transaction-related expenses and charges | 6,242,915 | 3,445,247 | 87,198 | +81.20% |
| Share-based incentive and stock options | 164,030 | 3,702,351 | 12,787,122 | -95.57% |
| Share of profit or loss of joint ventures and associates | (216,110) | 1,126,312 | (4,049,508) | N/M |
| Provisions for contingencies | 2,401,951 | 335,773 | 367,126 | +615.35% |
| Allowance for impairment of trade debtors | 5,630,839 | 7,032,818 | 753,428 | -19.93% |
| Allowance for obsolescence | 1,967,300 | 1,547,723 | 586,515 | +27.11% |
| Initial recognition and changes in the fair value of biological assets | (441,141) | (1,764,863) | 45,746 | -75.00% |
| Changes in the net realizable value of agricultural products after harvest | 346,277 | 1,540,776 | 2,385,069 | -77.53% |
| Gain on sale of equipment and intangible assets | 0 | (7,751,311) | (125,464) | -100.00% |
| Trade receivables (Working capital) | 51,097,375 | 23,764,716 | (40,786,580) | +115.01% |
| Other receivables (Working capital) | 8,574,580 | (916,362) | (4,967,150) | N/M |
| Income and minimum presumed income taxes (Working capital) | (3,366,121) | (6,997,089) | 4,782,508 | -51.89% |
| Inventories and biological assets (Working capital) | 27,437,305 | 36,367,436 | 15,023,507 | -24.56% |
| Trade and other payables (Working capital) | (39,080,791) | (40,860,354) | 1,270,082 | -4.36% |
| Employee benefits and social security (Working capital) | (917,004) | (1,166,946) | (2,289,095) | -21.42% |
| Deferred revenue and advances from customers (Working capital) | (1,758,908) | (128,698) | (21,087,704) | +1266.69% |
| Income taxes paid | (342,697) | 0 | (853,299) | N/M |
| Interest collected | 248,805 | 120,568 | 2,747,398 | +106.36% |
| Inflation effects on working capital adjustments | 44,660 | 139,914 | 321,103 | -68.08% |
| Net cash flows generated by operating activities from continuing operations | 77,162,236 | 41,287,004 | 30,930,816 | +86.89% |
| Net cash flows (used in)/generated by operating activities from discontinued operations | (11,151,173) | 8,618,607 | 10,785,770 | N/M |
| Net cash flows generated by operating activities | 66,011,063 | 49,905,611 | 41,716,586 | +32.27% |
| Proceeds from sale of property, plant and equipment | 139,923 | 390,381 | 336,726 | -64.16% |
| Net cash received from business combination | 0 | 0 | 37,508 | N/M |
| Net cash outflow from deconsolidation of subsidiary | (25,287) | 0 | 0 | N/M |
| Proceeds from financial assets | 737,658 | 19,270,288 | 888,140 | -96.17% |
| Investment in financial assets | (1,021,273) | (11,182,107) | (7,208,218) | -90.87% |
| Purchase of property, plant and equipment | (1,053,612) | (5,178,951) | (8,492,554) | -79.66% |
| Capitalized development expenditures | (2,474,879) | (5,339,782) | (7,094,693) | -53.65% |
| Purchase of intangible assets | (89,769) | (350,843) | (1,137,071) | -74.41% |
| Net cash flows used in investing activities from continuing operations | (3,787,239) | (2,391,014) | (22,670,162) | +58.39% |
| Net cash flows used in investing activities from discontinued operations | (2,076,440) | (3,737,877) | (6,058,093) | -44.45% |
| Net cash flows used in investing activities | (5,863,679) | (6,128,891) | (28,728,255) | -4.33% |
| Proceeds from borrowings | 88,386,288 | 266,390,032 | 135,818,247 | -66.82% |
| Repayment of borrowings and financed payments | (148,244,840) | (291,324,731) | (112,614,437) | -49.11% |
| Interest payments | (13,406,328) | (18,165,853) | (24,575,170) | -26.20% |
| Other financial payments | (4,523,759) | (3,208,933) | (2,746,945) | +40.97% |
| Purchase of own shares | 0 | (926,899) | (734,388) | -100.00% |
| Sales of own shares | 488,293 | 0 | 0 | N/M |
| Leased assets payments | (4,289,095) | (5,405,955) | (3,314,216) | -20.66% |
| Cash dividend distributed by subsidiary | 0 | (72,051) | (174,800) | -100.00% |
| Net cash flows used in financing activities from continuing operations | (81,589,441) | (52,714,390) | (8,341,709) | +54.78% |
| Net cash flows (used in)/generated by financing activities from discontinued operations | 2,879,907 | 2,008,287 | (1,714,158) | +43.40% |
| Net cash flows used in financing activities | (78,709,534) | (50,706,103) | (10,055,867) | +55.23% |
| Net decrease in cash and cash equivalents from continuing operations | (8,214,444) | (13,818,400) | (81,055) | -40.55% |
| Net (decrease) / increase in cash and cash equivalents from discontinued operations | (10,347,706) | 6,889,017 | 3,013,519 | N/M |
| Net (decrease) / increase in cash and cash equivalents | (18,562,150) | (6,929,383) | 2,932,464 | +167.88% |
| Inflation effects on cash and cash equivalents | (321) | 2,557 | (31,918) | N/M |
| Cash and cash equivalents as of beginning of the year | 32,695,079 | 44,473,270 | 48,129,194 | -26.48% |
| Effect of exchange rate changes on cash and equivalents | (2,333,822) | (4,851,365) | (6,556,470) | -51.89% |
| Cash reclassified to assets subject to foreclosure | (555,828) | 0 | 0 | N/M |
| Cash and cash equivalents as of the end of the year | 11,242,958 | 32,695,079 | 44,473,270 | -65.61% |
Funding the Future: R&D and Expansion Spending
Research and development represents the primary innovation engine for Bioceres. The group executes R&D activities through internal discovery teams and strategic collaborations with external academic institutions and public entities.
For the fiscal year ended June 30, 2026, total R&D spending amounted to $14,435,179, comprising $11,033,441 in expensed research costs and $3,401,738 in capitalized development expenditures. This compares to total R&D spending of $18,070,046 in fiscal year 2025 ($9,455,598 expensed and $8,614,448 capitalized) and $20,228,298 in fiscal year 2024 ($8,372,532 expensed and $11,855,766 capitalized).
- Active Pipeline Projects: As of June 30, 2026, the company maintained 23 active research and development projects covering seed traits, biological crop protection, adjuvants, biostimulants, and formulation platforms.
- Capital Expenditures (Capex): Outflows for property, plant, and equipment purchases were $1,053,612 in fiscal year 2026, down from $5,178,951 in fiscal year 2025 and $8,492,554 in fiscal year 2024, reflecting a disciplined capital allocation strategy focused on operational consolidation.
🗺️ The Corporate Family Tree: Structure & Investments
Subsidiaries, Associates, & Shared Ventures
Bioceres operates through a network of legal entities across key global agricultural jurisdictions. The table below outlines the principal subsidiaries and joint ventures held directly or indirectly by Bioceres Crop Solutions Corp. as of June 30, 2026:
| Subsidiary / Joint Venture Name | Jurisdiction of Incorporation | Direct/Indirect Ownership Interest (%) | Voting Interest (%) |
|---|---|---|---|
| BCS Holding Inc. | United States | 100% | 100% |
| Bioceres Crops do Brasil Ltda. | Brazil | 100% | 100% |
| Bioceres Crops S.A. | Argentina | 90% | 90% |
| Bioceres Semillas S.A.U. | Argentina | 80% | 80% |
| Comer. Agrop. Rizobacter de Bolivia S.A. | Bolivia | 80% | 80% |
| Insumos Agroquímicos S.A. | Argentina | 61% | 61% |
| Natal Agro S.R.L. (Associate) | Argentina | 31% | 31% |
| Pro Farm Group, Inc. | United States | 100% | 100% |
| Rasa Holding LLC | United States | 100% | 100% |
| Rizobacter Argentina S.A. | Argentina | 80% | 80% |
| Rizobacter Colombia SAS | Colombia | 80% | 80% |
| Rizobacter del Paraguay S.A. | Paraguay | 80% | 80% |
| Rizobacter do Brasil Ltda. | Brazil | 80% | 80% |
| Rizobacter France SAS | France | 80% | 80% |
| Rizobacter South Africa | South Africa | 76% | 76% |
| Rizobacter Uruguay | Uruguay | 80% | 80% |
| Rizobacter USA, LLC | United States | 80% | 80% |
| Synertech Industrias S.A. (Joint Venture) | Argentina | 40% | 40% |
| Trigall Genetics S.A. (Joint Venture) | Uruguay | 50% | 50% |
| Verdeca LLC | United States | 100% | 100% |
Strategic Investments & Minority Stakes
The company maintains joint ventures and strategic investments to access external innovation and co-develop specialty formulations:
- Synertech Industrias S.A.: A 50/50 joint venture between Rizobacter and De Sangosse (resulting in a 40% indirect Group interest) operating a micro-beaded fertilizer plant in Pergamino, Argentina.
- Trigall Genetics S.A.: A 50/50 joint venture with French wheat breeder Florimond Desprez focused on deregulating and commercializing GM wheat varieties featuring the HB4 trait across South America.
- Moolec Science SA Holding: The Group holds convertible notes and shares in Moolec Science SA. Following financial distress, Moolec’s shareholders approved a voluntary winding-up in October 2026. As of June 30, 2026, the Group recognized an expected credit loss allowance of $7.7 million against related receivables.
- Natal Agro S.R.L.: In February 2026, Bioceres disposed of a 20% equity stake in Natal Agro S.R.L., reducing its ownership from 51% to 31%, resulting in a loss of control and shifting the investment to equity-method accounting.
👥 Power & Control: Who Pulls the Strings?
The Brain Trust: Board of Directors & Executive Leadership
The company’s leadership team and board of directors guide its strategic initiatives, research priorities, and financial restructurings:
- Federico Trucco, Ph.D. (Chief Executive Officer and Executive Director): Age 49. Served as CEO of Bioceres S.A. from 2011 to 2019 and as CEO of Bioceres Crop Solutions Corp. since its public listing in 2019. Holds a Ph.D. in crop sciences and a CBA from the University of Illinois, a Master’s degree in plant pathology from Colorado State University, and a Bachelor’s degree in biochemistry from Louisiana State University.
- Ezequiel Simmermacher (Chief Financial Officer): Age 40. Appointed CFO on January 5, 2026. Previously served as Director of Operational Excellence & Business Development for South America at CHS Inc. and Regional Finance Director for South America at CHS Inc. Holds an Executive MBA from IAE Business School and an Industrial Engineering degree from ITBA.
- Yogesh Mago (Non-Executive Director): Age 45. Director since July 12, 2022. Senior Advisor for Ospraie Ag Science LLC since 2016, with over 15 years of investment experience across agriculture, travel, and industrial sectors. Holds a Bachelor’s degree in Finance and International Business from New York University.
- Antonio Simon Vumbaca (Non-Executive Director): Age 55. Director since November 5, 2025. Specializes in cross-border structuring, crisis arbitration, and governance. Serves as Chair of AIG’s Board and non-executive director of Elemental Altus.
- Duraiswami (“D”) Narain (Non-Executive Director): Age 63. Director since December 29, 2025. Served as CEO and Managing Director of Bayer CropScience Limited in India from 2018 to 2023, and previously as Global Treasurer and CEO of India operations for Monsanto Company. Chartered accountant holding an MBA from the Kellogg School of Management.
Who Owns the Stock?
As of October 31, 2026, the company had 63,815,891 ordinary shares issued and outstanding. The table below sets forth beneficial ownership for major shareholders holding 5% or more of the outstanding stock:
| Beneficial Owner | Number of Ordinary Shares Beneficially Owned | Percentage of Total Outstanding Stock (%) |
|---|---|---|
| Jasper Lake Ventures One LLC | 8,710,707 | 13.6% |
| Bioceres LLC | 6,221,079 | 9.8% |
| Ospraie Management LLC | 6,233,590 | 9.8% |
| Solel Partners LP | 4,579,364 | 7.2% |
| Agriculture Investment Group Corp. | 3,722,732 | 5.8% |
🎯 The Strategic Outlook: Future Plans & Potential Pitfalls
Competitive Advantages & Economic Moats
Bioceres maintains several distinct structural advantages within the agricultural input and biotech markets:
- First-Mover Trait Advantage: HB4 is the world’s first and only commercially approved drought-tolerant trait technology in wheat, and the first approved Latin American biotech event in major global crops.
- Global Biological Leadership: Holds an estimated 23% global market share in biological soybean inoculants via Rizobacter, providing an established international brand identity.
- Capital-Efficient R&D Architecture: Employs open-architecture co-development partnerships with research institutes, reducing early-stage technology discovery costs.
- Established Distribution Networks: Commercial relationships with over 1,600 dealers and corporate partnership distribution agreements with major agricultural multinationals, including Syngenta.
What Could Go Wrong? Key Challenges & Business Risks
The group faces significant operational, financial, and regulatory risks disclosed in its annual filing:
- Substantial Doubt About Going Concern: The Group faces severe liquidity constraints, a working capital deficit of $54.9 million as of June 30, 2026, and upcoming short-term debt maturities, generating substantial doubt regarding its ability to continue as a going concern.
- Ongoing Secured Note Litigation & Judgment: Following a default acceleration in November 2025, noteholders obtained a court judgment of approximately $110.1 million against Bioceres and its guarantors in September 2026, which is currently under appeal.
- Nasdaq Delisting Risk: Received a deficiency letter from Nasdaq on March 16, 2026, due to trading below the $1.00 minimum bid price, subsequently transferring to the Nasdaq Capital Market with an extension through March 15, 2027 to regain compliance.
- Latin American Macroeconomic Volatility: Heavy operational concentration in Argentina exposes the group to currency devaluations, foreign exchange access controls, export duties, and regional economic uncertainty.
- Rizobacter Share Injunction: An ongoing legal dispute dating back to a 1995 share transfer affects 44% of Rizobacter’s capital stock, including shares held by Rasa Holding, exposing the company to contingent obligations for which a $3.5 million provision has been recorded.
The Next Chapter: Growth & Expansion Initiatives
To navigate liquidity challenges and position its product portfolio for long-term growth, management is executing several strategic initiatives:
- Pivot to HB4 Trait Licensing: Restructuring the HB4 seed business away from direct seed production toward a light-capital trait licensing model, partnering with leading breeders such as Grupo Don Mario (GDM) and the Colorado Wheat Research Foundation (CWRF).
- Biologicals Capacity Utilization: Scaling production across recently expanded facilities in Pergamino (biologicals) and Londrina (adjuvants) to meet international demand under the Syngenta agreement.
- Liability Management & Debt Refinancing: Restructuring short-term bank borrowings, having successfully refinanced $74.3 million of local financial debt at Rizobacter to extend maturities through 2028 and 2029.
The Verdict: Strategic Outlook & Conclusion
Bioceres Crop Solutions stands at a critical strategic junction. The company possesses an innovative agricultural biotechnology platform anchored by proprietary biological inoculants, high-performance adjuvants, and groundbreaking drought-tolerant HB4 trait technologies. However, near-term operational success depends directly on resolving its debt obligations, navigating the Secured Note litigation judgment, executing its pivot to a capital-light trait licensing model, and stabilizing its capital structure across South American operating units.
Official Site: www.biocerescrops.com
Note: Financial ratios, margins, year-over-year (YoY) growth rates, and percentage shares of revenue are calculated by FirmsWorld based on figures reported in the company’s official SEC filing.